Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NASDAQ | Common Stock
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States.
The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.
The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea.
Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 11, 24 | -0.12 Increased by +77.29% | -0.24 Increased by +51.80% |
| Aug 14, 24 | -0.37 Increased by +36.21% | -0.27 Decreased by -37.04% |
| May 13, 24 | -0.56 Decreased by -14.29% | -0.40 Decreased by -40.00% |
| Mar 4, 24 | -0.59 Decreased by -5.36% | -0.41 Decreased by -43.90% |
| Nov 13, 23 | -0.52 Decreased by -20.93% | -0.52 |
| Aug 7, 23 | -0.58 Decreased by -625.00% | -0.54 Decreased by -7.41% |
| May 15, 23 | -0.49 Increased by +5.77% | -0.52 Increased by +5.77% |
| Mar 6, 23 | -0.56 Increased by +11.11% | -0.32 Decreased by -75.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 2.56 M Decreased by -47.47% | -12.48 M Increased by +55.49% | Decreased by -488.11% Increased by +15.27% |
| Jun 30, 24 | 991.00 K Decreased by -85.71% | -20.02 M Increased by +36.41% | Decreased by -2.02 K% Decreased by -344.84% |
| Mar 31, 24 | 2.13 M Decreased by -65.37% | -30.70 M Decreased by -19.53% | Decreased by -1.44 K% Decreased by -245.16% |
| Dec 31, 23 | 3.00 M Decreased by -7.88% | -32.34 M Decreased by -10.10% | Decreased by -1.08 K% Decreased by -19.52% |
| Sep 30, 23 | 4.87 M Decreased by -55.00% | -28.03 M Decreased by -24.50% | Decreased by -576.08% Decreased by -176.67% |
| Jun 30, 23 | 6.93 M Decreased by -69.86% | -31.48 M Decreased by -698.96% | Decreased by -454.05% Decreased by -2.55 K% |
| Mar 31, 23 | 6.17 M Increased by +28.71% | -25.68 M Increased by +6.91% | Decreased by -416.55% Increased by +27.67% |
| Dec 31, 22 | 3.26 M Increased by +297.20% | -29.37 M Increased by +12.02% | Decreased by -900.67% Increased by +77.85% |